An open label,single dose study evalauating the pharmacokinetics of Apremilast and its metabolite,M12 in subjects with severe renal impairment

Trial Profile

An open label,single dose study evalauating the pharmacokinetics of Apremilast and its metabolite,M12 in subjects with severe renal impairment

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Jan 2017

At a glance

  • Drugs Apremilast (Primary)
  • Indications Renal impairment
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 09 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top